Vynca
United States
- Palo Alto, CA
- 31/01/2022
- Series C
- $30,000,000
Vynca enables high-quality, person-centered, goal-concordant care that reflects individuals’ wishes with their serious illness management platform that incorporates virtual palliative care services, advance care planning, care coordination, symptom management, whole-person care and provider engagement. The company’s comprehensive solution set empowers providers, individuals and their families to have meaningful conversations about future care preferences supported by a broad range of serious illness management services offered from a single point of trust to deliver successful value-based arrangements to healthcare organizations. With this approach, Vynca is able to ensure that personalized end-of-life care is available for every individual, every time.
- Industry Hospital & Health Care
- Website https://vyncahealth.com/
- LinkedIn https://www.linkedin.com/company/vynca/
NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)